KINEVAC (sincalide) by Bracco. Approved for cholecystokinin analog [epc]. First approved in 1976.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
KINEVAC (sincalide) is an intravenous cholecystokinin (CCK) analog approved in 1976 for diagnostic imaging of the biliary system. It stimulates gallbladder contraction and pancreatic secretion, enabling visualization during hepatobiliary scintigraphy. The drug is used to assess gallbladder function and detect biliary dyskinesia.
Late-lifecycle diagnostic agent with declining market relevance; teams are likely consolidating and focused on cost management rather than growth initiatives.
Cholecystokinin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
Working on KINEVAC offers limited career growth opportunities due to its LOE-approaching status and lack of active clinical development. Roles are primarily defensive and focused on margin protection and market maintenance rather than innovation and expansion.
Worked on KINEVAC at Bracco? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo